000 01395 a2200421 4500
005 20250518074627.0
008 ####s 0 0 eng d
022 _a1758-8340
024 7 _a10.1177/1758835919889001
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aQin, Shukui
245 0 0 _aA phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma.
_h[electronic resource]
260 _bTherapeutic advances in medical oncology
_c2019
300 _a1758835919889001 p.
_bdigital
500 _aPublication Type: Journal Article
700 1 _aChan, Stephen Lam
700 1 _aSukeepaisarnjaroen, Wattana
700 1 _aHan, Guohong
700 1 _aChoo, Su Pin
700 1 _aSriuranpong, Virote
700 1 _aPan, Hongming
700 1 _aYau, Thomas
700 1 _aGuo, Yabing
700 1 _aChen, Minshan
700 1 _aRen, Zhenggang
700 1 _aXu, Jianming
700 1 _aYen, Chia-Jui
700 1 _aLin, Zhong-Zhe
700 1 _aManenti, Luigi
700 1 _aGu, Yi
700 1 _aSun, Yongjian
700 1 _aTiedt, Ralph
700 1 _aHao, Lu
700 1 _aSong, Wenjie
700 1 _aTanwandee, Tawesak
773 0 _tTherapeutic advances in medical oncology
_gvol. 11
_gp. 1758835919889001
856 4 0 _uhttps://doi.org/10.1177/1758835919889001
_zAvailable from publisher's website
999 _c30436418
_d30436418